RIMS4 (regulating synaptic membrane exocytosis 4) is a protein localized to the presynaptic active zone that regulates synaptic vesicle exocytosis and membrane potential. However, the provided abstracts contain insufficient information to comprehensively describe RIMS4's molecular mechanism or primary synaptic function. The abstracts instead reveal RIMS4's emerging clinical relevance in cancer pathology rather than synaptic biology. RIMS4 hypermethylation appears as a hallmark biomarker in aggressive clear cell renal cell carcinomas with CpG island methylator phenotype (CIMP), correlating with poor patient outcomes 1. Additionally, RIMS4 was identified among cfDNA methylation biomarkers for early noninvasive pancreatic cancer detection, achieving 97% sensitivity in discovery cohorts 2. Intriguingly, network analysis of trauma patients identified RIMS4 as co-localized with complement receptor CD55 and other proteins in lipid raft microdomains associated with dysregulated inflammatory responses 3. RIMS4 was also prioritized as a candidate driver gene in pediatric neuroblastoma based on allele-specific expression patterns 4. These findings suggest RIMS4 methylation status has significant diagnostic and prognostic value across multiple cancer types, though direct functional mechanisms remain insufficiently characterized in the provided literature.